 Effects of Code Sepsis Implementation on ED Sepsis Care (Code Sepsis)    Protocol version: Version 9.0  Updated:  February 1, 2023  Principal Investigator:  [INVESTIGATOR_351421], MD, MSc      Trial steering committee: Ithan Peltan, MD, MSc    Samuel Brown, MD, MPH    Joseph Bledsoe, MD  Facilities involved: Intermountain Medical Center  Utah Valley Hospi[INVESTIGATOR_351422]:  National Institutes of Health (1K23 GM12966-01A1)     
Code Sepsis I protocol Version 3.0 
 1 TABLE OF CONTENTS  1.	ABBREVIATIONS	AND	DEFINITIONS	..........................................................................................	4	1.1 Abbreviations	...............................................................................................................................................	4	1.2 Definitions	.....................................................................................................................................................	5	2. STUDY SUMMARY	................................................................................................................................	6	2.1 Title	................................................................................................................................................................	6	2.2 Primary Objective	........................................................................................................................................	6	2.3 Primary Hypothesis	.....................................................................................................................................	6	2.4 Study Design	.................................................................................................................................................	6	2.4.1 Study groups and phases	..................................................................................................................................................	6	2.4.2 Inclusion criteria	...................................................................................................................................................................	6	2.4.3 Exclusion criteria	..................................................................................................................................................................	6	2.4.5 Primary analysis cohort	.....................................................................................................................................................	7	2.4.6 Primary outcome	.................................................................................................................................................................	7	2.4.7 Secondary outcomes	..........................................................................................................................................................	7	2.4.8 Data analysis	..........................................................................................................................................................................	7	2.4.9 Sample size	.............................................................................................................................................................................	7	3. TRIAL DESCRIPTION	.............................................................................................................................	8	3.1 Background	...................................................................................................................................................	8	3.2 Overall Study Motivation, Aim and Hypothesis	.....................................................................................	8	3.3 Primary Objective	........................................................................................................................................	9	3.4 Primary Hypothesis	.....................................................................................................................................	9	3.5 Study Overview	............................................................................................................................................	9	3.6 Analysis cohorts	.........................................................................................................................................	10	3.6.1 Primary analysis cohort	..................................................................................................................................................	10	3.6.2 Secondary and sensitivity analysis cohorts	..............................................................................................................	10	3.6.3 Subgroups	............................................................................................................................................................................	10	3.7 Endpoints	....................................................................................................................................................	10	3.7.1 Primary outcome	..............................................................................................................................................................	10	3.7.2 Secondary outcomes	.......................................................................................................................................................	10	4. STUDY POPULATION AND ENROLLMENT	.....................................................................................	12	4.1 Setting	..........................................................................................................................................................	12	4.2 Study Population	........................................................................................................................................	12	4.2.1 Exposure groups	................................................................................................................................................................	12	4.2.2 Inclusion criteria:	...............................................................................................................................................................	13	4.2.3 Exclusion criteria:	..............................................................................................................................................................	13	4.2.4 Inclusion/exclusion criteria rationale	.........................................................................................................................	[ADDRESS_436830] Care	.............................................................................................................................................	16	5.2 Code Sepsis Protocol	.................................................................................................................................	16	6. DATA COLLECTION AND VARIABLES	..............................................................................................	18	6.1 Data Collection	...........................................................................................................................................	18	6.2 Anonymous Data Collection For Protocol Development and During Live Code Sepsis Activation	.............................................................................................................................................................................	18	6.3 Active Follow-Up for Patients Undergoing Code Sepsis	......................................................................	18	
Code Sepsis I protocol Version 3.0 
 2 6.4 Protected Health Information	.................................................................................................................	18	6.5 Variables/data elements	..........................................................................................................................	18	6.6 Data Management	.....................................................................................................................................	20	7. DATA ANALYSIS	.................................................................................................................................	21	7.1 Introduction to Quasi-Experimental Analysis	.......................................................................................	21	7.2 Multivariable models	................................................................................................................................	21	7.3 Sample size/power analysis	.....................................................................................................................	[ADDRESS_436831] overtreatment and adverse drug reactions	......................................................................	25	8.4 Potential Benefits of the Proposed Research to Human Subjects and Others	................................	25	8.5 Importance of the Knowledge to be Gained	.........................................................................................	25	9. HUMAN SUBJECTS	............................................................................................................................	26	9.1 Selection of Subjects	.................................................................................................................................	26	9.2 Waiver of Informed Consent and HIPAA Authorization	......................................................................	26	9.2.1 Research involves no more than minimal risk	........................................................................................................	26	9.2.2 No adverse effects on the rights and welfare of participants	...........................................................................	26	9.2.3 The research could not practicably be carried out without waiver of informed consent	.......................	26	9.2.4 Information on the Code Sepsis protocol and study will be available to all ED patients	.........................	27	9.2.5 The minimal necessary amount of protected information will be obtained	...............................................	27	9.2.6 All data, including PHI, will be securely guarded from improper disclosure	................................................	27	10. MONITORING AND SAFETY REPORTING	.....................................................................................	28	10.1 Potential Risks and Benefits for Participants	......................................................................................	28	10.2 Adverse Event and Serious Adverse Event Collection	.......................................................................	28	10.2.1 Adverse event	..................................................................................................................................................................	28	10.2.2 Serious Adverse Event (SAE)	.......................................................................................................................................	[ADDRESS_436832] for independent safety monitor	..........................................................................................	31	10.5.6 Independent safety monitor responsibilities	........................................................................................................	31	10.6 Confidentiality During Adverse Event Reporting	...............................................................................	32	11. BIBLIOGRAPHY	................................................................................................................................	33	APPENDIX	A	—	Eligible	IV	and	IV-equivalent	antibiotics	....................................................	35	
Code Sepsis I protocol Version 3.0 
 3 APPENDIX	B	—	“Sepsis	mimic”	ICD	codes	.................................................................................	37	B.1	Heart	failure	diagnosis	codes1	..........................................................................................................	37	B.2	Pulmonary	embolism	diagnosis	codes1,2	.......................................................................................	38	B.3	Deep	vein	thrombosis	diagnosis	codes1,2	......................................................................................	39	APPENDIX	C	—	Diagnosis	codes	for	adverse	drug	reaction	................................................	42				
Code Sepsis I protocol Version 3.0 
 4 1. ABBREVIATIONS AND DEFINITIONS  1.1 Abbreviations  AE = Adverse event CHF = Congestive heart failure ED = Emergency Department GCS = Glasgow Coma Scale  HIPAA = Health Insurance Portability and Accountability Act IRB = Institutional Review Board ICU = Intensive Care Unit   ICD-9-CM = International Classification of Disease, version 9, clinical modification ICD-10-CM = International Classification of Disease, version 10, clinical modification INR = International normalized ratio  ISM = Independent safety monitor ITT = Intent to treat  MAP = Mean arterial pressure NIH = National Institutes of Health PE = Pulmonary embolism PI = Principle investigator PHI = Protected Health Information REDCap = Research Electronic Data Capture RR = Respi[INVESTIGATOR_351423] = Sequential Organ Failure Assessment score  SBP = Systolic blood pressure  SpO2 = Oxygen saturation via pulse oximetry  S[LOCATION_003]R = Serious and Unexpected Suspected Adverse Reactions  SAEs= Serious Adverse Events  WBC = White blood cell count     
Code Sepsis I protocol Version 3.0 
 5 1.2 Definitions  • Adverse Event: Any untoward medical occurrence associated with the use of a drug or a study procedure, whether or not considered drug related.  • Adverse reaction: An adverse reaction means any adverse event caused by a study intervention. An adverse reaction is a subset of all suspected adverse reactions where there is a reason to conclude that the study intervention caused the event.  • Door-to-antibiotic time: Primary outcome; the time from the first recorded arrival time in ED (usually ED triage or registration) and the time the first eligible antibiotic was administered.  • Hypotension: SBP <90 mmHg or MAP <65 mmHg or, where applicable, receipt of vasopressor medication • Intention to Treat (ITT): All eligible patients who present to the ED will be included in the ITT cohort for the purposes of analyzing the primary and secondary study outcomes.  • PHI: identifiable health information that is used, maintained, stored, or transmitted by a HIPAA-covered entity • SAEs: Serious Adverse Events Adverse events that are serious and unexpected and have a reasonable possibility that the event was due to a study procedure  • Sepsis: Life-threatening organ dysfunction resulting from a dysregulated host response to infection, clinically identified in the emergency department (ED) by [CONTACT_351481] (SOFA) score while in the ED ≥2 points above baseline plus suspected or confirmed infection in the ED.1 • Sepsis mimic: Clinical condition which may cause patient to exhibit and/or be treated for sepsis even though infection is not actually present. For the present study, pulmonary embolism (PE) and congestive heart failure (CHF) have been identified as sepsis mimic conditions. • Septic shock: Sepsis associated with hypotension requiring administration of vasopressors. • Study hospi[INVESTIGATOR_307]: Defined as the hospi[INVESTIGATOR_351424]. • Suspected adverse reaction: any adverse event for which there is a reasonable possibility that the study procedures caused the adverse event. Reasonable possibility means there is evidence to suggest a causal relationship between the study procedures and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction (21 CFR 312.32(a)).  • Suspected or confirmed infection in the emergency department: Identified based on clinical behaviors of clinicians as the combination of administration of an IV- or IV-equivalent antibiotic plus collection of a body fluid culture or a positive molecular test for infection. • Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R) An adverse reaction that is both unexpected (not consistent with the risks outlined in the protocol or investigator brochure), serious, and meets the definition of a Suspected Adverse Reaction      
Code Sepsis I protocol Version 3.0 
 6 2. STUDY SUMMARY  2.1 Title Effects of Code Sepsis Implementation on ED Sepsis Care (Code Sepsis)  2.2 Primary Objective Determine the effects of reorganizing ED sepsis care (Code Sepsis protocol) on door-to-antibiotic time for ED patients with sepsis.  2.3 Primary Hypothesis Early activation of a multidisciplinary, coordinated, team-based assessment and treatment protocol for patients with potential sepsis will decrease door-to-antibiotic time for ED patients with sepsis.  2.4 Study Design Pragmatic phase 2a pre/post single-center implementation study with contemporaneous controls testing reorganization of standard ED sepsis care around a protocol for early, coordinated, multidisciplinary protocol for assessment of patients with potential sepsis (Code Sepsis protocol). 1. We will emphasize pragmatic, real-world implementation of the Code Sepsis protocol in a single ED. 2. We will compare care delivered to ED patients after Code Sepsis protocol implementation in the intervention ED to care received in this ED prior to Code Sepsis implementation. 3. We will conduct a quasi-experimental analysis using contemporaneous control data obtained from two non-intervention hospi[INVESTIGATOR_351425]. 4. We will measure the effects of protocol implementation on all ED patients with sepsis (including patients not treated under the Code Sepsis protocol) as well as potential by[CONTACT_330120].  2.4.1 Study groups and phases Phase #1: Pre intervention (November 13, 2018 to November 12, 2019) • Control EDs: Standard care • Intervention ED: Standard care Phase #2: Intervention roll-in (November 13, 2019 to February 12, 2020) • Control EDs: Standard care • Intervention ED: Launch and fine-tuning of Code Sepsis protocol, fine tuning of Code Sepsis activation mechanism.  Phase #3: Full intervention (February 13, 2020 to February 12, 2021) • Control EDs: Standard care • Intervention ED: Full implementation of Code Sepsis protocol  2.4.2 Inclusion criteria 1. Age ≥18 years 2. Arrival to intervention or a control ED during study period  2.4.3 Exclusion criteria 1. Age <18 years 
Code Sepsis I protocol Version 3.0 
 7 2. Trauma patient  2.4.5 Primary analysis cohort ED patients with clinical sepsis, as identified by [CONTACT_135764] 1) Acute organ failure: SOFA score while in the ED ≥2 points above baseline 2) Suspected or confirmed infection while in the ED, as identified by [CONTACT_17588]: a) Administration of ≥1 IV or IV-equivalent antibiotics while in the ED b) Collection of ≥1 body fluid cultures while in the ED  2.4.6 Primary outcome Door-to-antibiotic time  2.4.7 Secondary outcomes • Mortality (including 30-day, 1-year, hospi[INVESTIGATOR_307]) • Hospi[INVESTIGATOR_7960] • Hospi[INVESTIGATOR_7577] • Code Sepsis activation rate  • Code Sepsis activation accuracy • Antibiotic utilization fraction • Antibiotic spectrum • Antibiotic overtreatment rate • Adverse drug & allergic reaction incidence (e.g. anaphylaxis, new onset Clostridium difficile infection)  2.4.8 Data analysis The primary analysis will use quasi-experimental methods to compare sepsis patients’ adjusted mean door-to-antibiotic time (primary outcome) at the intervention hospi[INVESTIGATOR_14587]- versus post-implementation of the Code Sepsis protocol using the measured change at non-intervention hospi[INVESTIGATOR_351426]-versus post-intervention changes not attributable to protocol implementation. Secondary analyses will compare the change in secondary outcomes using similar methods.   2.4.9 Sample size Assuming 4.5 sepsis patients per day at the intervention ED, treatment of 30% of these patients by [CONTACT_351482] #3, and 6 total sepsis patients daily in control EDs (all conservative estimates), I will have 90% power to detect a change ≥16 minutes in the overall average door-to-antibiotic time among all ED sepsis patients after Code Sepsis implementation at the intervention hospi[INVESTIGATOR_307].    
Code Sepsis I protocol Version 3.0 
 8 3. TRIAL DESCRIPTION  3.1 Background  Sepsis, the combination of infection and acute organ dysfunction, is a common, morbid, and often lethal syndrome.1,2 Sepsis hospi[INVESTIGATOR_351427] 1.3 million patients each year, kills 20%, and costs $23.7 billion.2-4 Early, appropriate antibiotic initiation is critical: sepsis survival decreases with every hour’s delay. 5-13 While guidelines and government mandates thus emphasize prompt antibiotics, international guidelines’ have admitted a lack of data to support the feasibility or implementation of their one-hour door-to-antibiotic goal.14,15  Among patients presenting to the emergency department (ED) with sepsis, we previously found that non-patient contextual cues could improve rapid antibiotic initiation, whereas ED busyness was associated with delayed antibiotics.16,[ADDRESS_436833], ED protocols linking prehospi[INVESTIGATOR_351428] a multidisciplinary, team-based response are common and effective for trauma, stroke, and myocardial infarction,18-22 conditions that are less common and less mortal than sepsis but require similarly time-sensitive treatment.23 Given that sepsis has a less definitive presentation, however, analogous protocols for sepsis could waste resources or promote anchoring bias and overtreatment of patients without sepsis, issues observed with door-to-antibiotic standards for pneumonia.24-26   We hypothesize that reorganizing ED sepsis care around multidisciplinary “Code Sepsis” teams activated prior to or upon patients’ ED arrival will reduce door-to-antibiotic times — with tolerable overtreatment rates — by [CONTACT_351483], systematizing illness severity and infection risk assessment,[ADDRESS_436834] completion, and eliminating any gap between treatment decision and antibiotic infusion. This study will therefore evaluate the effectiveness and tradeoffs of a Code Sepsis program for ED sepsis patients.  3.2 Overall Study Motivation, Aim and Hypothesis Many emergency department (ED) patients with sepsis do not receive antibiotics and other care within intervals recommended in international guidelines. Efforts to accelerate treatment, however, may lead to overtreatment and other adverse effects. The goal of this project is to determine the potential effectiveness and tradeoffs of a Code Sepsis program for ED sepsis patients.  Aim:   Establish the feasibility and effects of a team-based Code Sepsis protocol designed to accelerate antibiotic initiation for ED patients with suspected sepsis.     Using preexisting infrastructure, implement prehospi[INVESTIGATOR_307]- or triage-activated Code Sepsis ED teams in a single ED and compare sepsis patients’ door-to-antibiotic times pre- and post-implementation, controlling for unrelated temporal trends with observational data from two non-intervention EDs.   Hypothesis: Prehospi[INVESTIGATOR_351429]-based activation of an ED team prepared to rapi[INVESTIGATOR_351430]-to-antibiotic time without increasing overtreatment.  
Code Sepsis I protocol Version 3.[ADDRESS_436835] of reorganizing ED sepsis care (Code Sepsis protocol) on door-to-antibiotic time for ED patients with sepsis.  3.[ADDRESS_436836] the preliminary efficacy of ED-based Code Sepsis teams activated on or before patients’ ED arrival, we will pursue a Phase 2a implementation trial involving Code Sepsis team activation in one ED (Intermountain Medical Center [IMC]) while collecting contemporaneous control data at two other urban EDs (Utah Valley Hospi[INVESTIGATOR_351431] [control sites], Table 1). • Months 1-12: Collect baseline data (all sites), refine Code Sepsis protocol, and train ED staff at IMC. Portions of baseline data may be collected in a retrospective fashion. At the intervention site during this period, we may also undertake preparatory work to Code Sepsis protocol launch, including anonymous patient care observations to evaluate care processes; pi[INVESTIGATOR_351432]; and testing of the accuracy of Code Sepsis activation mechanisms.  • Months 13-15: Run-in period: implement Code Sepsis protocol at IMC, optimize protocol & its trigger. • Months 25-36: Continue Code Sepsis protocol at site A (intervention ED). Continue standard care processes for sepsis without change (control condition) at two non-intervention EDs Using contemporaneous controls and rigorous statistical methods, we will assess how implementation of the Code Sepsis protocol affects process and patient outcomes in the intervention ED (Figure 1). Continuation of the Code Sepsis protocol (with or without revision) by [CONTACT_351484]/or adoption elsewhere within the Intermountain Healthcare system is expected to be contingent on the results of these analyses.     Figure 1. Code Sepsis implementation and data collection for Aim III. 

Code Sepsis I protocol Version 3.0 
 10 3.6 Analysis cohorts 3.6.1 Primary analysis cohort ED patients with clinical sepsis, as identified by [CONTACT_135764] 1) Acute organ failure: SOFA score while in the ED ≥2 points above baseline 2) Suspected or confirmed infection while in the ED, as identified by [CONTACT_17588]: c) Administration of ≥1 IV or IV-equivalent antibiotics while in the ED (see Appendix A) d) Collection of ≥1 body fluid cultures while in the ED  3.6.2 Secondary and sensitivity analysis cohorts 1) All eligible ED patients 2) ED patients with a “sepsis mimic” diagnosis based on a primary ICD-10 discharge diagnosis codes for congestive heart failure or venous thromboembolism with no diagnostic code for infection (see Appendix B).  3) “Likely” sepsis patients based on simple triage assessment to include fever and at least 1 out of 3 of hypotension (SBP <90 mmHg), altered mental status (GCS ≤14), or respi[INVESTIGATOR_1399] (RR ≥22 or SpO2 ≤85%).  3.6.3 Subgroups A priori subgroups will include: sex; hypotension (SBP <90 mmHg or MAP <65 mmHg) present on ED arrival.  3.[ADDRESS_436837] recorded arrival time in ED (usually ED triage or registration) and the time the first eligible antibiotic was administered (Appendix A).  3.7.2 Secondary outcomes • Clinical/patient-centered secondary outcomes (measured among all ED sepsis patients): 1) All-cause mortality to day 30  2) All-cause mortality to 1 year  3) In-hospi[INVESTIGATOR_351433]-cause mortality  4) Hospi[INVESTIGATOR_7960]: Amount charged to patient for their medical care during index ED visit and associated hospi[INVESTIGATOR_059]. 5) Hospi[INVESTIGATOR_7577]  • Process/feasibility secondary outcomes 1) Code Sepsis activation rate: Measured as the percentage of all ED patients for whom the Code Sepsis protocol was activated.  2) Code Sepsis activation accuracy metrics. Accurate Code Sepsis activation is defined as activation for patients who have sepsis while in the ED and no activation for patients who do not have sepsis in the ED.  • Adverse effects and unintended outcomes of protocol implementation 
Code Sepsis I protocol Version 3.0 
 11 1) Antibiotic utilization percentage: measured as the fraction of  (1) all ED patients; (2) Code Sepsis activation patients; or (3) “likely” sepsis patients who received IV or IV-equivalent antibiotics. 2) Antibiotic spectrum: Total Stenehjem antibiotic spectrum score28 for all antibiotics administered in first 24 hours, measured for (1) all ED patients or (2) sepsis patients 3) Antibiotic overtreatment rate: Percentage of “sepsis mimic” patients who received IV or IV-equivalent antibiotics in the ED. 4) New onset C. difficile colitis incidence: Percentage of (1) all ED patients and (2) ED sepsis patients with a positive stool test for Clostridium difficile colitis between 72 hours and 90 days after ED arrival. 5) Adverse drug & allergic reaction incidence: Measured as the fraction of 1) all ED patients and (2) ED sepsis patients with a discharge diagnosis code consistent with anaphylaxis or with an adverse reaction to antibiotics (see Appendix C).  • Potential exploratory outcomes 1) Measures of organ failure trajectory, to include change in the SOFA score between hospi[INVESTIGATOR_19156] 1 and hospi[INVESTIGATOR_19156] 3, and overall and organ-specific measures of organ failure-free days through day 28.  § Organ-failure free days (OFFD) are defined as the number of days from the time of the first SOFA score ≤[ADDRESS_436838] two consecutive calendar days after the SOFA score ≤1 above baseline and continued SOFA score ≤1 point above baseline to day 28. If a patient has SOFA score rise again to ≥2 points above baseline and subsequently achieves SOFA score ≤[ADDRESS_436839] period of SOFA score ≤1 to day 28. If a patient had SOFA score ≥2 points above baseline at day 27 or dies prior to day 28, OFFD will be zero § Support-free days (i.e. ventilator-free days) are calculated similar to OFFD 2) Mortality at other intervals 3) Testing and treatment utilization. Outcomes measured among (1) among all ED sepsis patients; (2) all ED patients; (3) “likely” sepsis patients 4) Code Sepsis care process timing: measured among patients who received Code Sepsis protocol activation as time from protocol activation until completion of key protocol steps, to include blood culture collection, chest X-ray collection, team huddle, antibiotic initiation 5) Timing of testing & care processes among all sepsis patients, to include ED clinician assessment, ED room placement, ED departure, blood culture collection, radiology testing, and order entry for antibiotics. Measured analogous to door-to-antibiotic time. 6) Code Sepsis protocol adherence: measured as performance of protocol steps in correct order both individually and as a fraction of all possible.   
Code Sepsis I protocol Version 3.0 
 12 4. STUDY POPULATION AND ENROLLMENT  4.1 Setting Intermountain Healthcare (hereafter “Intermountain”) is a nonprofit health system based in Salt Lake City, Utah with 23 hospi[INVESTIGATOR_351434]. Code Sepsis implementation will occur in a teaching ED (IMC, my “home” hospi[INVESTIGATOR_307]) providing 89,000 visits annually (2.8% with clinical sepsis) for an  economically and ethnically diverse population of 1.1 million in Salt Lake County, Utah plus referrals from Wyoming, Nevada, and Idaho. To avoid spi[INVESTIGATOR_39472], concurrent control data will be electronically abstracted from two Intermountain EDs (Utah Valley Hospi[INVESTIGATOR_351431]) staffed by [CONTACT_351485] (Table 1).  4.2 Study Population We will study adult, non-trauma patients from the IMC ED and two control EDs during three phases (Figure 1): baseline ([ADDRESS_436840] care at all sites); run-in (3 months, IMC ED launches/fine tunes the Code Sepsis protocol); and Code Sepsis implementation ([ADDRESS_436841] care in control EDs). For this pre/post implementation trial, in which there will be no direct patient contact [CONTACT_351486] a new, redesigned standard care processes in a non-randomized fashion, all ED patients who meet inclusion and do not meet exclusion criteria will be included in the analysis.  4.2.1 Exposure groups The group within which patient is analyzed is determined by [CONTACT_135764] (1) when the patient presents to the ED and (2) which hospi[INVESTIGATOR_307]/ED to which the patient presents (Figures 1 and 2).  A. Pre-implementation control group at non-intervention hospi[INVESTIGATOR_600]: Admission to ED at non-intervention hospi[INVESTIGATOR_600] (Utah Valley Hospi[INVESTIGATOR_351431]) prior to Code Sepsis implementation (estimated N=135,000) B. Pre-implementation control group at intervention hospi[INVESTIGATOR_307]: Admission to ED at IMC prior to Code Sepsis implementation (estimated N=100,000) C. Post-implementation control group at non-intervention hospi[INVESTIGATOR_600]: Admission to ED at non-intervention hospi[INVESTIGATOR_600] (Utah Valley Hospi[INVESTIGATOR_351431]) after implementation of Code Sepsis protocol at IMC (estimated N=170,000) D. Exposure group: Admission to ED at IMC during full Code Sepsis implementation (estimated N=125,000)  Table 1. Study hospi[INVESTIGATOR_351435]/teaching [ADDRESS_436842] allocation by [CONTACT_351487][INVESTIGATOR_351436] I protocol Version 3.0 
 13 4.2.2 Inclusion criteria: o ED patient at Intermountain Medical Center, Utah Valley Hospi[INVESTIGATOR_307], Dixie Regional Medical Center o ED arrival beginning 1 year prior to date of Code Sepsis implementation at Intermountain Medical Center and continuing through 15 months after Code Sepsis implementation date.  o Age ≥18 years  4.2.3 Exclusion criteria: o Age <18 years o Trauma patient  4.2.4 Inclusion/exclusion criteria rationale Patients <18 years of age are excluded because the mechanisms, manifestations, and management of sepsis in children <[ADDRESS_436843] protocols.  As such, prehospi[INVESTIGATOR_351429]-based sepsis prediction models applicable to adults are unlikely to work for children <18 years. Due to the above issues, implementation of a single sepsis care protocol for individuals age <18 years and age ≥[ADDRESS_436844] and triggers preexisting team-based care protocols with options for prehospi[INVESTIGATOR_351437].   4.2.5 Study phase dates ED patients arriving to study EDs will be assigned to a study phase based on their ED arrival date. • Phase #1 (pre-intervention analysis phase): November 13, 2018 to November 12, 2019 • Phase #2 (intervention roll-in): November 13, 2019 to February 12, 2020 • Phase #3 (full intervention analysis phase): February 13, [ADDRESS_436845] care will be carried out under a waiver of informed consent and HIPAA authorization (see section 9).  4.4 Minorities and Women  Women and minorities will be enrolled in proportion to their representation in the population base from which this study was developed, specifically patients presenting to Intermountain hospi[INVESTIGATOR_351438]’s Salt Lake, Washington, and Weber Counties.  In order to provide generalizable data for the ED patient diagnosis groups studied in each Aim, there will be no specific selection criteria that differ between sex/gender and racial/ethnic groups. Hospi[INVESTIGATOR_351439] a combined population of over 1.5 million individuals, including over 26% who are Hispanic or non-white race. We expect the sex, ethnic and racial mix of the enrolled patients to reflect the population served.  4.5 Vulnerable Subjects We anticipate that potentially vulnerable subjects are eligible for the study. Potentially vulnerable patient subjects include pregnant women, prisoners, and/or individuals with decisional impairment. The purpose of this project is to identify a cohort that reflects the diversity of the U.S. sepsis population. Therefore, we believe these individuals should not be excluded from the study since the study is of no more than minimal risk. 
Code Sepsis I protocol Version 3.[ADDRESS_436846] cohort.  2. Altered mental status is also a common manifestation or complication of sepsis. Excluding patients with decisional impairment would therefore severely bias results of the planned analyses. 3. In implementation studies such as this, it is generally not possible to exclude vulnerable subjects. Aim III’s intervention involves testing a new option for standard care for ED sepsis management, so excluding vulnerable populations could actually subject these patients to harm because exclusion would prevent their receiving standard care. Assessment for vulnerability status, moreover, would largely preclude the planned intervention by [CONTACT_351488][INVESTIGATOR_351440].   
Code Sepsis I protocol Version 3.[ADDRESS_436847] care for ED sepsis patients, specifically implementation of Code Sepsis protocol at Intermountain Medical Center. The study will include three phases with two groups during each phase. The primary analysis will only use data from phases #1 and #3 (see Figure 1 and 2). Phase #0: Protocol development (1 year, overlaps with phase #1) • Control EDs: N/A • Intervention ED: A small number of suspected sepsis patients (<10) may undergo anonymous observation to understand care processes involved in ED sepsis care. In addition, testing and iterative optimization of the accuracy of the Code Sepsis activation may employ direct observation of care for a convenience sample of patients during ED triage and comparison of activation criteria to clinician judgment, final sepsis diagnosis based on chart review, and electronic sepsis queries. Finally, pi[INVESTIGATOR_351441] a small convenience sample of patients (<20) identified by [CONTACT_351489]. We will collect anonymous data about completion of Code Sepsis processes during pi[INVESTIGATOR_48124]. Phase #1: Pre intervention (1 year) • Control EDs: Standard care • Intervention ED: Standard care.  Phase #2: Intervention roll-in • Control EDs: Standard care • Intervention ED: Launch and fine-tuning of Code Sepsis protocol, fine tuning of Code Sepsis activation mechanism.  Phase #3: Full intervention • Control EDs: Standard care • Intervention ED: Full implementation of Code Sepsis protocol Phase #4 (operational): Continuation of the Code Sepsis protocol (with or without revision) by [CONTACT_351484]/or adoption elsewhere within the Intermountain Healthcare system is expected to be contingent on observed effects of protocol implementation. It is possible that an inadequate benefit/risk ratio could lead to a decision not to continue the Code Sepsis protocol.    
Code Sepsis I protocol Version 3.[ADDRESS_436848] Care Patients arriving to the control EDs (all study phases) and the intervention ED during study Phase #[ADDRESS_436849], and standardized order sets.  5.2 Code Sepsis Protocol The Code Sepsis protocol (Figure 3) has six steps developed in collaboration with ED-based study team members and ED leaders (including physicians, nurses, pharmacists, and others) from the implementation ED and the Intermountain system. The current draft protocol was further iteratively revised based on input derived from the proposed multidisciplinary team during in situ high-fidelity simulation and during informal/ad hoc operationally-oriented pi[INVESTIGATOR_351442] 1-5 during live patient care.  The below protocol will be adapted further prior to and after implementation to ensure the protocol is feasible, efficient, and functions as intended based on stakeholder input and, as needed, additional protocol element testing during simulation and/or live patient care. Further revision will occur, during the protocol run-in phase and as needed based on observed findings and stakeholder input.  
 Figure 3. Current Code Sepsis protocol based on iterative revision using simulation testing, stakeholder input, & live pi[INVESTIGATOR_48124].  1) Identify likely sepsis patient from prehospi[INVESTIGATOR_351443] (nurse), at ED triage (nurse/physician), or on ED room placement (nurse or physician), adapting local and national practice for stroke team activation.29,30  2) Mobilize ED personnel and equipment to meet patients on arrival to the ED room using methods and communication networks already developed for ED trauma and stroke teams. 3) Concurrent patient evaluation and data collection by [CONTACT_351490] (20-25 minutes), to include bedside assessment (e.g. history, examination, vital signs, allergy and medication history) by [CONTACT_099], nurse and pharmacist; IV placement; blood and urine sampling; point-of-care laboratory testing, including lactate and urinalysis; and portable X-ray imaging. Appropriate therapeutic interventions will continue in parallel during the nominal data collection phase. 4) Team “huddles” to decide if sepsis diagnosis has been confirmed, disproven, or remains indeterminate. The physician may complete this step by [CONTACT_351491]-making to the team at any time. The nurse will request a decision huddle at 25 minutes into the Code Sepsis event if it has not previously been performed.  

Code Sepsis I protocol Version 3.0 
 17 5) Proceed with next therapeutic and/or diagnostic steps including, for confirmed sepsis patients, immediate initiation of an appropriate antibiotic regimen chosen from a range of options contained in a Code Sepsis antibiotic pack brought to the bedside by a pharmacist on protocol activation. Code Sepsis antibiotic regimens have been selected based on published guidelines and local antibiotic resistance patterns with input from ED clinicians, pharmacists, and infectious disease/antibiotic stewardship personnel. 6) If initial huddle pronounced sepsis status as “indeterminate,” return to step #4 after additional 20-25 minutes to follow up on additional diagnostic results (e.g. urinalysis, complete blood count 7) For antibiotic-treated patients, follow-up by [CONTACT_351492]-escalation or cessation as appropriate.  Additional protocol elements/details: • Code Sepsis team members:  o   ED attending physician +/- ED resident physician or medical student o   ED triage nurse o   ED unit coordinator (i.e. unit secretary) o   ED nurses x2 o   ED patient care technician o   ED phlebotomist x1-[ADDRESS_436850] as available o   ED X-ray technician • Code Sepsis electronic order entry: Code Sepsis order sets for diagnostic evaluation and antibiotic treatment will be constructed and activated at the intervention ED's electronic medical record with the beginning of study Phase #2. Order sets will help speed up diagnostic testing and treatment initiation, aid care standardization, and facilitate Code Sepsis event tracking and data collection.   • Code Sepsis clinical team training: With active support from intervention hospi[INVESTIGATOR_351444]'s system-wide ED leadership team, the Code Sepsis ED Implementation Team will provide clinical staff in the implementation ED with training on the Code Sepsis protocol during the months prior to study Phase #2. Primary training will include distribution of instructional materials, direct education at clinical staff meetings, targeted in-person education, and in situ simulation. Primary training will complete early in study Phase #2, with consolidation training, protocol reminders, physician detailing, and targeted clinician reeducation continuing through study Phase #3.    
Code Sepsis I protocol Version 3.[ADDRESS_436851] for collection of identifiable data or specimens.  6.1 Data Collection Intermountain’s Enterprise Data Warehouse (EDW) is a centrally-managed, well-curated, and accessible database linking system-wide clinical, billing, laboratory, and other data.[ADDRESS_436852] queries to bedside clinicians will be employed as needed to supplement electronically-available data. This encounter level data will be linked to additional data on hospi[INVESTIGATOR_320955], physician and nurse staffing. Long-term mortality data will be obtained through a preexisting linkage to Utah state death records and/or the federal Social Security Death Index. Encounter data will be linked to data on race, ethnicity, and hospi[INVESTIGATOR_614] (admit date, type, diagnoses, and costs) stored in the Utah Population Databank. We will employ a preexisting linkage to Utah State death records and the federal Social Security Death Index for mortality ascertainment.   6.[ADDRESS_436853] protocol parameters, including team composition and process completion times. In addition, a convenience sample of intervention hospi[INVESTIGATOR_20889] (<10) with sepsis may be observed during the pre-Code Sepsis implementation phase to understand care processes involved in sepsis care. No identifying information about the patient or clinical team will be recorded.  6.[ADDRESS_436854], a member of the study team will actively monitor Code Sepsis activation patients every 1-3 days until hospi[INVESTIGATOR_19156] #7. There will be no direct patient contact.  6.[ADDRESS_436855] for data completion and verification.  6.5 Variables/data elements • Patient medical record number(s) • Patient encounter ID code • Hospi[INVESTIGATOR_307]/facility • Date of birth • Age • Sex • Race 
Code Sepsis I protocol Version 3.0 
 19 • Ethnicity • Marital status • Preferred language • Insurance status/type • Address/zip code (for determination of residence at a nursing facility or other long-term care facility and estimation of socioeconomic status) • Social Security Number (to assist matching of encounter data to Social Security Death Index and Utah state death records) • ED disposition • Hospi[INVESTIGATOR_44417] • Date/time of all events related to ED visit and hospi[INVESTIGATOR_059] (e.g. ED arrival & departure, hospi[INVESTIGATOR_063] & discharge) • Date/time antibiotics administered • Antibiotic utilization • APACHE II score • APACHE IV score • Acute physiology score • Charlson index • Elixhauser index • SOFA score • Baseline SOFA score over preceding 10 years • Source of admission (e.g. home, SNF, LTAC, outside hospi[INVESTIGATOR_307]) • Source of infection • Clinician infection determination, patient illness severity, sepsis status, and agreement with Code Sepsis activation • Sepsis presence/absence • Culture results • Admission diagnosis • Mode of arrival to ED • ED triage data including triage acuity score • Resident involvement in ED care • Results of all laboratory testing • Date/time of all laboratory testing  • ED length of stay • ED vital signs • ED medications • ED interventions/procedures • Date/time, elapsed time, and type of ED events including provider interaction, room placement, disposition • Date/time of diagnostic testing, vasopressor initiation and other interventions, and management • Date/time of interventions • Date/time of blood or body fluid cultures • Discharge diagnosis and procedure codes  • Billing diagnosis and procedure codes • Diagnosis-related group • Hospi[INVESTIGATOR_351445] I protocol Version 3.0 
 20 • In-hospi[INVESTIGATOR_34380] • Long-term mortality (e.g. 30d, 90d and 1y mortality) • Healthcare charges • ED patient census • Number of ED beds • ED patient flow (including counts of patient arrivals, boarding, and admissions) • Attending physician ED staffing • Nurse staffing • Trauma registration status • Allergies • Adverse drug reaction events and date/time • Code Sepsis team activation (Y/N) • Code Sepsis activation date/time  • Code Sepsis care process completion date/times • Code Sepsis team function • Code Sepsis team composition (by [CONTACT_10757]) • Code Sepsis process adherence  6.[ADDRESS_436856] it in a custom-designed computer database. Data abstraction from electronic medical records will employ either standardized paper data sheets or a custom-designed interface maintained within Intermountain’s secure Research Electronic Data Capture (REDCap) platform.[ADDRESS_436857] of implementing a team-based Code Sepsis protocol for ED sepsis patients by [CONTACT_351493]-adjusted process and patient-centered outcomes before versus after protocol implementation at a single hospi[INVESTIGATOR_307]. Results from simple pre/post analyses, however, may be subject to misinterpretation due to secular trends (changes in the measured outcomes over time not attributable to the study intervention). Analyses of Aim III primary and secondary outcomes will therefore employ quasi-experimental methods to eliminate confounding due to secular trends when estimating the effect of Code Sepsis implementation on outcomes. More complex methods of quasi-experimental analysis includes interrupted time series and regression discontinuity, but are analogous to the relatively simpler approach called difference-in-difference analysis (Figure 4).33 Difference-in-difference analysis uses multivariable linear regression to compare the adjusted mean door-to-antibiotic time (primary outcome) at the intervention hospi[INVESTIGATOR_14587]- versus post-implementation of the Code Sepsis protocol using the measured change at non-intervention hospi[INVESTIGATOR_351426]-/post-intervention changes not attributable to protocol implementation.34 This model tests the difference in intervention ED versus non-intervention EDs’ differences in outcome before versus after the Code Sepsis implementation (Figures 4-5). The b3 parameter from the regression model depi[INVESTIGATOR_6517] [ADDRESS_436858].   7.2 Multivariable models Multivariable models will be adjusted for demographic and clinical parameters with known or plausible associations with both door-to-antibiotic time and treatment hospi[INVESTIGATOR_307], presentation before or after Code Sepsis implementation, and/or Code Sepsis activation. Evaluation of secondary outcomes will employ an analogous approach using multivariable linear, Poisson, or logistic regression as appropriate. Repeating the quasi-experimental analysis for the primary and key secondary outcomes after stratification (rather than adjustment) by (1) sex and (2) hypotension present versus absent on ED arrival will allow evaluation of whether these patient characteristics modify the effects of Code Sepsis implementation. In order to measure how the Code Sepsis protocol influences the care of its core target population, we will perform analyses comparing selected outcomes among the subset of patients who have ED triage data suggesting a strong possibility of sepsis. Outcomes to be evaluated in the sensitivity analyses will include door-to-antibiotic time, antibiotic treatment fraction, and antibiotic treatment spectrum.  7.3 Sample size/power analysis Using 2013 to 2017 data from our study hospi[INVESTIGATOR_600], we estimated conservatively that the intervention ED provides care for 1,650 sepsis patients annually (approximately 4.5 sepsis patients per day) and the  Figure 4. Difference-in-differences analysis  𝒀𝒊=𝛽"ERA#+𝛽$HOSP+𝜷𝟑𝐄𝐑𝐀𝒊×𝐇𝐎𝐒𝐏𝒊+𝛽&(Z#) Figure 5. Simplified difference-in-differences equation. Yi is the door-to-antibiotic time for patient i, HOSP and ERA are, respectively, indicator variables for care at the intervention hospi[INVESTIGATOR_351446], and Z is a vector of covariates. b3 is the coefficient of interest. 

Code Sepsis I protocol Version 3.0 
 22 control EDs together care for a total of 2,200 sepsis patients annually (approximately 6 sepsis patients per day). Based on the design and our pi[INVESTIGATOR_351447], a very conservative estimate of door-to-antibiotic time for patients who receive antibiotics after evaluation under the Code Sepsis protocol is 50 minutes. By [CONTACT_2163], our preliminary data from 2013 to 2017 indicates current mean (SD) door-to-antibiotic time for ED sepsis patients is 170 (±75) minutes and that only 5% of patients currently receive antibiotics within 1 hour of ED arrival. Assuming (again conservatively) that the Code Sepsis protocol is activated for 30% of sepsis patients treated in the intervention ED during the full implementation phase (study phase #3), we will have 90% power to detect a difference-in-differences change of [ADDRESS_436859] could include identify loss of privacy, medicolegal liability, theft, embarrassment, or harassment.  8.1.2 Risks for control group patients Aside from issues discussed above, there are no foreseeable risks for ED patients receiving care at a non-intervention hospi[INVESTIGATOR_351448] #1 and #2. Sepsis patients arriving to control hospi[INVESTIGATOR_351449].   8.1.3. Risks to patients exposed to the Code Sepsis protocol  Patients presenting to the intervention hospi[INVESTIGATOR_351450] #2 and 3 (run-in implementation and full implementation) will be exposed to and may receive care using the “Code Sepsis” version of standard care. The Code Sepsis protocol is designed to accelerate evaluation, testing, and treatments that the patient would have eventually received under now current standard care. The Code Sepsis intervention is therefore expected to pose no more than minimal risks to ED patients exposed to the protocol, including specifically sepsis patients for whom the Code Sepsis protocol is activated. The potential risks to subjects due to this protocol include:  1) Adverse drug reactions or antibiotic-associated infections related to unnecessary or overtreatment antibiotic treatment with prespecified regimens. 2) Delay in diagnosis of non-infectious problems due to focus on sepsis or infection related to Code Sepsis activation. 3) Delay in care related to resource allocation away from non-Code Sepsis patients without sepsis (by[CONTACT_351494]).  4) For sepsis patients for whom the Code Sepsis protocol is not activated (i.e. by[CONTACT_351495]), delay in care related to lower index of suspi[INVESTIGATOR_351451].    8.2 Alternatives to Participation There are no alternatives to participation in this pragmatic before/after implementation research study.  8.3 Minimization of Risks Federal regulations at 45 CFR 46.111(a)(1) require that risks to subjects are minimized by [CONTACT_196750]. We will review the electronic medical record of all Code Sepsis activations for potential adverse effects related to study procedures. This will include review of standardized Code Sepsis documentation incorporated into clinical care as part of the care redesign. While there are no foreseeable effects of data collection on the care of patients who receive standard care at the control hospi[INVESTIGATOR_600] (all study phases) or during the pre-intervention phase at Intermountain Medical Center, monitoring of aggregate data quality will include all hospi[INVESTIGATOR_351452]. As necessary, after consultation with the Independent Safety Monitor, study procedures (including the Code Sepsis protocol) will be adjusted or even halted if important adverse effects are 
Code Sepsis I protocol Version 3.[ADDRESS_436860] identity and prevention of unintentional release of protected information is of paramount importance to the research team.  • Data storage and transfer: Data will be maintained in password-protected, encrypted research servers, REDCap (a secure, HIPAA-compliant system), or password-protected, encrypted computers. Patient identifiers for prehospi[INVESTIGATOR_351453] I will be provided in secure, encrypted electronic format to Department of Health staff for identification of ambulance patient care reports. Matched records will be returned in secure, encrypted electronic format. All devices will have been approved by [CONTACT_351496] (during matching of ED data to prehospi[INVESTIGATOR_139245]) the Utah Department of Health for use with clinical and research data. Both Intermountain and the State of Utah deploy comprehensive information technology support systems to maintain and regularly update computer systems and maintain physical and electronic safeguards for data management. Any paper case report forms will only include study identification numbers, and will be stored in a locked file cabinet. Datasets used for statistical analyses will be deidentified. • Data access: Only the PI [INVESTIGATOR_351454]. All individuals with access to identifiable data will have all necessary human subjects training, including Good Clinical Practice training as required by [CONTACT_351497].  • Training: All study personnel will maintain appropriate training in human subjects research and data protection. The PI, primary mentor, and study staff responsible for study coordination, data collection, and data management of the associated clinical trial will maintain Good Clinical Practice training as per NIH policy (NOT-OD-16-148).  8.3.[ADDRESS_436861] medicolegal risk Data on subjects studied in the proposed aims will be kept confidential in accordance with applicable laws and statues.   8.3.4 Optimization of Code Sepsis targeting  Optimization of team activation mechanism during phase #2 of Aim III (intervention run-in and optimization) will help maximize false positive and minimize false negative team activations.   8.3.[ADDRESS_436862] overtreatment and anchoring bias Physicians and other providers will be educated intensively about the protocol, with particular emphasis on the corresponding concepts that (1) a sepsis team activation does not establish a sepsis diagnosis and (2) that the sepsis prediction tool was specifically not designed to capture all patients with sepsis and that, as a consequence, many patients with sepsis will not trigger a Code Sepsis.   
Code Sepsis I protocol Version 3.[ADDRESS_436863] involvement will also help minimize the risk of preventable adverse drug or allergic reactions.   8.4 Potential Benefits of the Proposed Research to Human Subjects and Others This study has the potential to generate important findings for patients with sepsis and their treating clinicians, including methods to identify sepsis patients at ED triage or in the prehospi[INVESTIGATOR_6885].  Sepsis patients treated in the intervention ED after implementation of the full Code Sepsis protocol could receive faster evaluation, diagnosis, and treatment initiation, leading to improved patient outcomes. The risks to patient confidentiality and the risks for adverse drug reactions appear substantially less than the potential benefit to sepsis patient subjects and the important knowledge gained about delivery of ED sepsis care.  8.5 Importance of the Knowledge to be Gained Patients with sepsis —a syndrome defined by [CONTACT_351498] — have high mortality. This syndrome is also common, affecting nearly 3% of ED patients in our data. Early antibiotic initiation improves sepsis outcomes, but many ED patients do not receive timely antibiotics. The overall hypothesis of this phase 2a study is that reorganizing standard ED sepsis care around multidisciplinary “Code Sepsis” teams activated prior to or immediately upon patients’ ED arrival will reduce door-to-antibiotic times. Aim III of this proposal will determine whether the Code Sepsis protocol is feasible, safe, and effective at decreasing door-to-antibiotic time. Data from human subjects are also necessary to validate triage- or prehospi[INVESTIGATOR_307]-based sepsis prediction models that can be customized by [CONTACT_351499], intensive resource mobilization (as is planned here) for sepsis care, or to aid risk/benefit decisions for sepsis treatments with more than minimal risks (Aim I) and to understand how practice patterns or systems of care may be optimized to accelerate time-dependent treatment while minimizing unintended consequences (Aim II). The no-more-than-minimal risks to subjects from observational research (Aims I and IIA), interviews (Aim IIB), or systematically reorganizing sepsis care to accelerate evaluations and treatments patients would receive anyway under current standard care (Aim III) are acceptable in the context of the important knowledge to be gained to improve care for the common and deadly sepsis syndrome.   
Code Sepsis I protocol Version 3.[ADDRESS_436864] of a system-level intervention on the organization of ED sepsis care using an augmented pre-/post-intervention design. In the post-intervention period, the studied intervention — early activation of ED teams for patients likely to have sepsis — will be adopted as standard care at Intermountain Medical Center. As such, no patients arriving to any ED during the pre-intervention or to a non-intervention control ED will be exposed to the intervention. Conversely, all patients arriving to the Intermountain Medical Center ED in the post-intervention phase will be exposed to the intervention.   9.1 Selection of Subjects Federal regulations at 45 CFR 46(a)(3) require the equitable selection of subjects. All eligible patients will be enrolled. Study exclusion criteria neither unjustly exclude classes of individuals from participation in the research nor unjustly include classes of individuals from participation in the research. Hence, the recruitment of subjects conforms to the principle of distributive justice.   9.[ADDRESS_436865] a waiver of informed consent and HIPAA authorization based on the following criteria as per 45 CFR 46.116(d) and the HIPAA Privacy Rule.  9.2.[ADDRESS_436866] care, and will merely accelerate evaluation, testing, and treatment sepsis patients would receive during current (pre-intervention) standard care, patients will overall experience only the risks associated with standard ED clinical care. Research and registry creation involve no direct contact [CONTACT_351500], only review of records routinely collected for administration and medical care. For a small number of subjects, there will be anonymized monitoring of ED operations in the form of non-interactive observation of Code Sepsis protocol completion involving collection of anonymous data, which would be standard during implementation of any approach to improving standard ED care.   9.2.[ADDRESS_436867] the rights or welfare of subjects.  9.2.3 The research and registry could not practicably be carried out without waiver of informed consent Given the large number of eligible patient subjects (up to 530,000, including approximately 9,450 patients with sepsis in the primary analysis cohort), the research and registry could not practicably be carried out without the waiver of consent. The sample size for this chart review is large enough that including only those data for which consent could be obtained would prohibit conclusions to be drawn 
Code Sepsis I protocol Version 3.0 
 27 and would compromise the scientific validity of the study, as a large proportion of the data would be eliminated if obtaining consent were a requirement. Obtaining consent would also preclude rapid initiation of the Code Sepsis protocol and rapid antibiotic initiation. The subjects whose records will be reviewed will not be followed beyond their hospi[INVESTIGATOR_059] (except for routine use of data on long-term mortality obtained via existing linkages) and would be mostly lost to follow up. The proportion of subjects who have relocated or have passed away will likely be a significant percentage of the subject population, and so the research results would not be meaningful and would lose statistical power if obtaining consent were a requirement.  9.2.4 Information on the Code Sepsis protocol and study will be available to all ED patients We will make available patient information sheets describing the Code Sepsis protocol in the intervention emergency department (e.g. lobby, patient information stations, and on request). It is otherwise not possible to provide patient subjects with information about the study as there is no feasible mechanism by [CONTACT_320970], attempting to do so would substantially increase the risk of a confidentiality breach, and because the information that is found will have no impact on subjects’ clinical care.  9.2.5 The minimal necessary amount of protected information will be obtained Only data necessary for the completion of the study will be collected. The patient ID, encounter ID, social security number, address, and date of birth are necessary to allow data linkage, identification of the specific patient encounter for supplemental data abstraction. Event date/times are necessary for care process and outcome measurement, including calculation of the elapsed time related to various patient management actions include the primary outcome. Identifiers will maintained in the registry to facilitate future research.  9.2.[ADDRESS_436868], for other research as approved by [CONTACT_2717], or for other research for which the use or disclosure of protected health information would be permitted by [CONTACT_351501]. Minimal identifiers will be maintained linked to the data. Maintaining minimal identifiers linked to the data is necessary to allow (1) manual abstraction of additional data from the electronic medical record and (2) potential future linkage – with IRB approval -- of the data to additional datasets. No individual subject data will be presented in any presentation, publication or report related to this research. Data will be presented only in anonymized or aggregate or as results of statistical analyses and will not include any individual-level data that could be traced to a particular subject.     
Code Sepsis I protocol Version 3.0 
 28 10. MONITORING AND SAFETY REPORTING  On the basis of established precedents in implementation research, using toolkits supplied by [CONTACT_351502]’s CTSA-supported Institute for Translational Health Sciences and in consultation with the Intermountain Institutional Review Board (IRB) and National Institutes of Health (NIH) staff, we believe the proposed clinical trial represents no more than minimal risk to exposed patients. The study will thus be overseen by [CONTACT_202421] (ISM), a practicing ICU physician with extensive experience performing clinical trials but not affiliated with the current trial.  10.1 Potential Risks and Benefits for Participants • Potential risks: The risk level associated with this study is estimated to be no more than minimal, since the studied intervention — prehospi[INVESTIGATOR_351455]-based Code Sepsis teams — will be adopted as standard care and is designed to accelerate evaluation, testing, and treatments that the patient would have eventually received under current standard care. While the efficient coordination of therapi[INVESTIGATOR_351456], we will monitor for the possibility of effects potentially relevant to faster antibiotic therapy, specifically receipt of antibiotics to which the patient is known to be allergic. This possibility is protected against through inclusion of a pharmacist in the Code Sepsis team. Other risks are also minimal and related to loss of confidentiality of data. • Potential benefits: The potential benefits to study subjects with sepsis treated in the intervention ED after implementation of the full Code Sepsis protocol include faster evaluation, diagnosis, and treatment initiation leading to improved patient outcomes.  10.[ADDRESS_436869] be evaluated by [CONTACT_978]. The PI, with assistance from study co-investigators as needed, will assess whether there is a reasonable possibility that the study procedure caused the event, based on the criteria below. Investigators will also consider whether the event is unanticipated or unexplained given the patient’s clinical course, previous medical conditions, and concomitant medications. If the severe adverse event is judged to be reportable, as outlined below, then the investigator will report to the ISM and IRB his assessment of the potential relatedness of each adverse event to protocol procedure.  The study uses the following AE attribution scale: • Definitely Related: The event follows: a) A reasonable, temporal sequence from a study procedure; and b) Cannot be explained by [CONTACT_11564]’s clinical state or other therapi[INVESTIGATOR_014]; and c) Evaluation of the patient’s clinical state indicates to the investigator that the experience is definitely related to study procedures.  • Probably or Possibly Related: The event should be assessed following the same criteria for “Definitely Associated”. If in the investigator’s opi[INVESTIGATOR_274365], then “probably” or “possibly” associated should be selected.  • Probably Not Related: The event occurred while the patient was on the study but can reasonably be explained by [CONTACT_11564]’s clinical state or other therapi[INVESTIGATOR_014].  
Code Sepsis I protocol Version 3.0 
 29 • Definitely Not Related: The event is definitely produced by [CONTACT_102]’s clinical state or by [CONTACT_274437]. • Uncertain Relationship: The event does not meet any of the criteria previously outlined.  10.2.2 Serious Adverse Event (SAE) An SAE is any AE that results in any of the following outcomes: • Death • A life-threatening experience (that is, immediate risk of dying) • Event requiring prolongation of existing hospi[INVESTIGATOR_059]. As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm: Report if admission to the hospi[INVESTIGATOR_274358] a result of the adverse event. Emergency room visits that do not result in admission to the hospi[INVESTIGATOR_11241] (e.g., life-threatening; required intervention to prevent permanent impairment or damage; other serious medically important event). • Persistent or significant disability/incapacity. As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm: Report if the adverse event resulted in a substantial disruption of a person's ability to conduct normal life functions, i.e., the adverse event resulted in a significant, persistent or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities and/or quality of life. • Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_312753], based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.   10.2.3 Adverse event monitoring The PI [INVESTIGATOR_351457]’s ED visit. The PI [INVESTIGATOR_351458] [ADDRESS_436870], regardless of the investigator's opi[INVESTIGATOR_25289]. Thereafter, serious adverse events are not required to be collected unless routine clinical care monitoring or the PI [INVESTIGATOR_351459], probably, or definitely to the Code Sepsis protocol.   10.[ADDRESS_436871] of study procedures (or of uncertain relationship). The following are examples of events that will be considered routinely recorded clinical outcomes: • Death not related to study procedures.  • Adverse drug reaction (excluding anaphylaxis associated with antibiotic administration) not related to study procedures • Secondary and healthcare associated infections • Persistent or progressive organ failure 
Code Sepsis I protocol Version 3.0 
 30 • Prolonged hospi[INVESTIGATOR_351460] 72 hours of identification all AEs that are serious and possibly, probably, or definitely related to study procedure (or of uncertain relationship) or are unexpected. If the ISM concurs with the PI’s assessment, the AE will be reported to the IRB within [ADDRESS_436872]-of-care therapi[INVESTIGATOR_14953] a more efficient, expeditious, and coordinated manner, the safety monitoring plan will be implemented with the use of an Independent Safety Monitor (ISM). The ISM will monitor participant safety, evaluate the progress of the study, review procedures for maintaining the confidentiality of data, and monitor the quality of data collection, management, and analyses. The PI [INVESTIGATOR_351461] a timely manner. The ISM will have full capacity to end the study at her/his discretion if there is an important safety signal, according to a safety monitoring charter that will be finalized in consultation with NIH and the ISM before study launch. Notably, given that the “intervention” in this trial is a non-randomized implementation of a bundle of timely care for sepsis treatment, the safety monitoring plan will focus on monitoring the Code Sepsis activations. The PI [INVESTIGATOR_60414]’ safety and that the study is conducted according to the IRB-approved research plan on a daily basis.   10.5.[ADDRESS_436873]-of-care therapi[INVESTIGATOR_14953] a more efficient, expeditious, and coordinated manner, the foundation for safety monitoring for this study is the routine quality assurance monitoring of the study hospi[INVESTIGATOR_307]’s Emergency Department. This quality assurance activity includes review of incident reports for clinical adverse events. The ED physician who serves as site medical director and currently has lead responsibility for monitoring of care quality and safety in each study ED. The study team will be in monthly contact [CONTACT_351503][INVESTIGATOR_351462], probably, or definitely related to Code Sepsis implementation. If necessary, comparisons to control hospi[INVESTIGATOR_351463]. 2. Specific to study procedures, all Code Sepsis activations will be individually evaluated. The PI [INVESTIGATOR_351464] a monthly basis. AEs will be reported to the ISM in aggregate on a quarterly basis. The PI [INVESTIGATOR_351465] 72 hours of identification all AEs that are serious and possibly, probably, or definitely related to study procedure (or of uncertain relationship) or are unexpected. The ISM and PI [INVESTIGATOR_351466] (SAEs). If disagreement persists after discussion between the ISM and PI, the ISM will make the final decision about the status of the possible SAE. SAEs will be reported to the IRB within [ADDRESS_436874] (DSMB) of clinical experts and members with 
Code Sepsis I protocol Version 3.[ADDRESS_436875] the safety of study subjects, the quality of data, and the integrity of the study. The PI [INVESTIGATOR_351467]. Data verification for key demographic, exposure, and outcome parameters will be performed on an ongoing basis for a random 5% of all Code Sepsis patients. This will occur on the basis of data reabstraction by [CONTACT_351504]. The results of the ongoing data review will be incorporated into each review with the ISM. A statement reflecting the results of the ongoing data review will be incorporated into the annual report for the IRB.   10.5.3 Frequency of data and safety monitoring  The PI [INVESTIGATOR_351468], either in-person or by [CONTACT_338927], to review study progress, data quality, and participants’ safety. A summary report on all adverse events and data quality will be submitted to the IRB during annual recertification as per IRB guidelines.  10.5.4 Independent safety monitor identify and affiliation The following individual has agreed to serve as the independent safety monitor for the study: Eliotte Hirshberg, MD, MS Division of Pulmonary & Critical Care Medicine, Intermountain Medical Center Associate Professor of Medicine, University of Utah School of Medicine  10.5.[ADDRESS_436876] Statement which includes current affiliations, if any, with pharmaceutical and biotechnology companies (e.g., stockholder, consultant), and any other relationship that could be perceived as a conflict of interest related to the study and/or associated with commercial interests pertinent to study objectives.  10.5.6 Independent safety monitor responsibilities • Review and approve the research protocol and plans for data safety and monitoring; • Evaluate the progress of the trial, including periodic assessments of data quality and timeliness, recruitment, accrual, participant risk versus benefit, and other factors that can affect study outcome; 
Code Sepsis I protocol Version 3.0 
 32 • Consider factors external to the study when relevant information becomes available, such as scientific or therapeutic developments that may have an impact on the safety of the participants or the ethics of the trial; • Review study performance, make recommendations and assist in the resolution of problems reported by [CONTACT_978]; • Protect the safety of the study participants; • Make recommendations to the PI [INVESTIGATOR_201127], termination or other modifications of the trial based on the observed adverse effects of the treatment under study; • Ensure the confidentiality of the study data and the results of monitoring; and, • Assist the IRB by [CONTACT_351505], enrollment, sample size, and/or data collection.  10.[ADDRESS_436877] international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.  2. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the [LOCATION_002]. Crit Care Med. 2013;41:1167–74.  3. Torio CM, Moore BJ. National Inpatient Hospi[INVESTIGATOR_41251]: The Most Expensive Conditions by [CONTACT_351506], 2013: Statistical Brief #204. Healthcare Cost and Utilization Project. 2016. Available at: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospi[INVESTIGATOR_307]-Conditions.jsp.: Accessed July 6, 2017. 4. Kaukonen K-M, Bailey M, Suzuki S, Pi[INVESTIGATOR_4444] D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308–16.  5. Peltan ID, Mitchell KH, Rudd KE, et al. Physician variation in time to antimicrobial treatment for septic patients presenting to the emergency department. Crit Care Med. 2017;45:1011–8.  6. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med. 2001;345:1368–77.  7. ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. New Engl J Med. 2014;370:1683–93.  8. ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, et al. Goal-directed resuscitation for patients with early septic shock. New Engl J Med. 2014;371:1496–506.  9. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.  10. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.  11. Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospi[INVESTIGATOR_351469]. Am J Respir Crit Care Med. 2017;196:856–63.  12. Seymour CW, [LOCATION_001] State Office of Quality and Patient Safety, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. New Engl J Med. 2017;376:2235–44.  13. Peltan ID, Brown SM, Bledsoe JR, et al. Emergency department door-to-antibiotic time and long-term mortality in sepsis. Chest. 2019.  14. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486–552.  15. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018;44:925–8.  16. Peltan ID, Mitchell KH, Rudd KE, et al. Prehospi[INVESTIGATOR_351470]-to-antibiotic time in sepsis. Ann Am Thorac Soc. 2018;15:1443–50.  17. Peltan ID, Bledsoe JR, Oniki TA, et al. ED crowding is associated with delayed antibiotics for sepsis. Ann Emerg Med. 2018.  18. MacKenzie EJ, Rivara FP, Jurkovich GJ, et al. A national evaluation of the effect of trauma-center care on mortality. New Engl J Med. 2006;354:366–78.  19. Kim SK, Lee SY, Bae HJ, et al. Pre-hospi[INVESTIGATOR_351471]-to-needle time for IV tPA in acute ischaemic stroke. Eur J Neurol. 2009;16:1331–5.  20. Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H. The impact of ambulance practice on 
Code Sepsis I protocol Version 3.0 
 34 acute stroke care. Stroke. 2007;38:2765–70.  21. Pedersen SH, Galatius S, Hansen PR, et al. Field triage reduces treatment delay and improves long-term clinical outcome in patients with acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2009;54:2296–302.  22. Sejersten M, Sillesen M, Hansen PR, et al. Effect on treatment delay of prehospi[INVESTIGATOR_351472] 12-lead electrocardiogram to a cardiologist for immediate triage and direct referral of patients with ST-segment elevation acute myocardial infarction to primary percutaneous coronary intervention. Am J Cardiol. 2008;101:941–6.  23. Seymour CW, Rea TD, Kahn JM, Walkey AJ, Yealy DM, Angus DC. Severe sepsis in pre-hospi[INVESTIGATOR_351473]: analysis of incidence, care, and outcome. Am J Respir Crit Care Med. 2012;186:1264–71.  24. Wachter RM, Flanders SA, Fee C, Pronovost PJ. Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med. 2008;149:29–32.  25. Singer M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification? Am J Respir Crit Care Med. 2017;196:800–2.  26. Klompas M, Calandra T, Singer M. Antibiotics for sepsis — Finding the equilibrium. JAMA. 2018;320:1433–4.  27. Croskerry P. From mindless to mindful practice--cognitive bias and clinical decision making. New Engl J Med. 2013;368:2445–8.  28. Stenehjem E, Hersh AL, Sheng X, et al. Antibiotic use in small community hospi[INVESTIGATOR_600]. Clin Infect Dis. 2016;63:1273–80.  29. Call K, Donohue M, Fontaine G, et al. Care Process Model: Emergency Management of Acute Ischemic Stroke. Intermountain Healthcare. 2017. Available at: https://intermountainhealthcare.org/ext/Dcmnt?ncid=520500199.: Accessed October 27, 2018. 30. George P, Wisco DR, Gebel J, Uchino K, Newey CR. Nurses are as specific and are earlier in calling in-hospi[INVESTIGATOR_351474]. J Stroke Cerebrovasc Dis. 2017;26:917–21.  31. Clayton PD, Narus SP, Huff SM, et al. Building a comprehensive clinical information system from components: the approach at Intermountain Health Care. Methods Inf Med. 2003;42:1–7.  32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.  33. Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014;312:2401–2.  34. Peltan ID, Brown CE, Burke AK, Chow EJ, Rowhani-Rahbar A, Crull MR. The July Effect on maternal peripartum complications before and after resident duty hour reform: a population-based retrospective cohort study. Am J Perinatol. Thieme Medical Publishers, 2017;34:818–25.     
Code Sepsis I protocol Version 3.0 
 35 APPENDIX A — Eligible IV and IV-equivalent antibiotics  Antibiotic Brand/alternative name [CONTACT_351527], Ambisome IV Ampi[INVESTIGATOR_351475]/sulbactam Unasyn IV Anidulafungin Eraxis IV Azithromycin Zithromax, Zmax, Sumamed IV Aztreonam Azactam IV Caspofungin Cancidas IV Cefazolin Ancef IV Cefdericol Fetroja IV Cefepi[INVESTIGATOR_351476]/avibactam Avycaz IV Ceftizoxime Cefizox IV Ceftolozane/tazobactam Zerbaxa, Ceftolozane IV Ceftriaxone Rocephin IV Cefuroxime Ceftin, Zinacef IV Chloramphenicol Chloromycetin IV Cidofovir Vistide IV Ciprofloxacin Cipro, Ciprobay, Ciproxin IV Clindamycin Cleocin IV Colistin Colymycin IV Dalbavancin Dalvance IV Daptomycin Cubicin IV Delafloxacin Baxdela IV Doripenem Doribax IV Doxycycline Doxychel, Vibramycin IV Eravacycline Xerava IV Ertapenem Invanz IV Erythromycin Erythocin, Erythroped IV Fidaxomycin Dificid PO Fluconazole Diflucan IV Ganciclovir Cytovene IV Gentamicin Garamycin IV Imipenem/cilastin Primaxin IV Isavuconazole Cresemba, Isavuconazonium IV Itraconazole Sporanox, Onmel IV Levofloxacin Levaquin IV Linezolid Zyvox IV 
Code Sepsis I protocol Version 3.0 
 36 Antibiotic Brand/alternative name [CONTACT_351528]/vaborbactam Vabomere IV Metronidazole Flagyl IV Micafungin Mycamine IV Minocycline Minocin IV Moxifloxacin Avelox IV Nafcillin Unipen, Nallpen IV Ofloxacin Floxin IV Omadadcycline Nuzyra, Paratek IV Oritavancin Orbactiv IV Oseltamavir Tamiflu PO Oxacillin Bastocillin IV Penicillin Penicillin V, Pencillin G, Pen VK, Bicillin, Veetids, Pentids, Permapen, [COMPANY_007]pen,  IV Peramavir Rapi[INVESTIGATOR_351477]/tazobactam Zosyn IV Plazomicin Zemdri IV Posaconazole Noxafil IV Quinuopristin/dalfopristin Synercid IV Remdesivir Veklury IV Rifampin Rifadin IV Telavancin Vibativ IV Tetracycline Achromycin, Tetracyn, Sumycin, Tetrachel IV Ticarcillin/clavulanate Timentin IV Tidezolid Sivextro IV Tigecycline Tygacil IV Tobramycin   IV Trimethoprim/sulfamethoxazole Bactrim, Septra, Sulfatrim IV Vancomycin Vancocin PO Vancomycin Vancocin IV Voriconazole Vfend IV Zanamivir Relenza IV    
Code Sepsis I protocol Version 3.0 
 37 APPENDIX B — “Sepsis mimic” ICD codes B.1 Heart failure diagnosis codes1  ICD-9  ICD-10  Description  398.,91  I09.81  Rheumatic heart failure 402.01  I11.0  Hypertensive heart disease with heart failure 402.11  I11.0  Hypertensive heart disease with heart failure 402.91  I11.0  Hypertensive heart disease with heart failure 404.01  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.03  I13.2  Hypertensive heart/kidney dz w/heart failure, stage [ADDRESS_436878] 404.11  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.13  I13.2  Hypertensive heart/kidney dz w/heart failure, stage [ADDRESS_436879] 404.91  I13.0  Hypertensive heart/kidney dz w/heart failure, stage 1-4 CKD or unspec 404.93  I13.2  Hypertensive heart/kidney dz w/heart failure, stage [ADDRESS_436880] 428.0  I50.9  Heart failure, unspecified 428.1  I50.1  Left heart failure 428.20  I50.20  Unspecified systolic heart failure 428.21  I50.21  Acute systolic heart failure 428.22  I50.22  Chronic systolic heart failure 428.23  I50.23  Acute on chronic systolic heart failure 428.30  I50.30  Unspecified diastolic heart failure 428.31  I50.31  Acute diastolic heart failure 428.32  I50.32  Chronic diastolic heart failure 428.33  I50.33  Acute on chronic diastolic heart failure 428.40  I50.40  Unspecified combined systolic and diastolic heart failure 428.41  I50.41  Acute combined systolic and diastolic heart failure 428.42  I50.42  Chronic combined systolic and diastolic heart failure 428.43  I50.43  Acute on chronic combined systolic and diastolic heart failure 428.9  I50.810  Right heart failure, unspecified 428.9  I50.811  Acute right heart failure 428.9  I50.812  Chronic right heart failure 428.9  I50.813  Acute on chronic right heart failure 428.9  I50.814  Right heart failure due to left heart failure 428.9  I50.82  Biventricular heart failure 428.9  I50.83  High output heart failure 428.9  I50.84  End stage heart failure 428.9  I50.89  Other heart failure 428.9  I50.9  Heart failure, unspecified  Use only if below is primary diagnosis and one of above is second diagnosis 425.4  I42.0  Dilated cardiomyopathy 425.5  I42.6  Alcoholic cardiomyopathy 425.9  I42.7  Cardiomyopathy due to drug and external agent 425.9  I42.8  Other cardiomyopathy 425.9  I42.9  Cardiomyopathy, unspecified 425.8  I43  Cardiomyopathy in diseases classified celsewhere 429.83  I51.81  Takotsubo cardiomyopathy  1 Adapted from: Heart Failure CCW Chronic Conditions Algorithm. CMS Chronic Conditions Data Warehouse. 2018. Available at: https://www.ccwdata.org/web/guest/condition-categories.: Accessed 
Code Sepsis I protocol Version 3.0 
 38 February 13, 2019.  B.2 Pulmonary embolism diagnosis codes1,2  ICD-9 ICD-10 Description (from ICD-10)  415.[ADDRESS_436881] trimester 673.24  O83.23 Thromboembolism in puerperium  Adapted from: 1. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy P-M, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041–1046.  2. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the [LOCATION_002]: evidence of overdiagnosis. Arch Intern Med 2011;171:831–837.     
Code Sepsis I protocol Version 3.0 
 39 B.3 Deep vein thrombosis diagnosis codes1,2  ICD-9 ICD-10 Description (from ICD-10)  451.11  I80.10 Phlebitis/thrombophlebitis of unspecified femoral vein 451.11  I80.11  Phlebitis/thrombophlebitis of right femoral vein 451.11  I80.12  Phlebitis/thrombophlebitis of left femoral vein 451.11  I80.13  Phlebitis/thrombophlebitis of bilateral femoral vein 451.19  I80.201 Phlebitis/thrombophlebitis of unspecified deep vessels of right lower extremity 451.19  I80.202 Phlebitis/thrombophlebitis of unspecified deep vessels of left lower extremity 451.19  I80.203 Phlebitis/thrombophlebitis of unspecified deep vessels of bilateral lower extremity 451.19  I80.209 Phlebitis/thrombophlebitis of unspecified deep vessels of unspecified lower extremity 451.19  I80.221 Phlebitis/thrombophlebitis of right popliteal vein  451.19  I80.222 Phlebitis/thrombophlebitis of right popliteal vein 451.19  I80.223 Phlebitis/thrombophlebitis of bilateral popliteal vein 451.19  I80.229 Phlebitis/thrombophlebitis of unspecified popliteal vein 451.19  I80.231 Phlebitis/thrombophlebitis of right tibial vein  451.19  I80.232 Phlebitis/thrombophlebitis of right tibial vein 451.19  I80.233 Phlebitis/thrombophlebitis of bilateral tibial vein 451.19  I80.239 Phlebitis/thrombophlebitis of unspecified tibial vein 451.19  I80.291 Phlebitis/thrombophlebitis of other deep vessels of right lower extremity 451.19  I80.292 Phlebitis/thrombophlebitis of other deep vessels of left lower extremity 451.19  I80.293 Phlebitis/thrombophlebitis of other deep vessels of bilateral lower extremity 451.19  I80.299 Phlebitis/thrombophlebitis of other deep vessels of unspecified lower extremity 451.81  I80.211  Phlebitis/thrombophlebitis of right iliac vein 451.81   I80.212 Phlebitis/thrombophlebitis of left iliac vein 451.81   I80.213  Phlebitis/thrombophlebitis of bilateral iliac vein 453.81   I80.219  Phlebitis/thrombophlebitis of unspecified iliac vein 451.11  I80.10 Phlebitis/thrombophlebitis of unspecified femoral vein 451.11  I80.11  Phlebitis/thrombophlebitis of right femoral vein 451.11  I80.12  Phlebitis/thrombophlebitis of left femoral vein 451.11  I80.13  Phlebitis/thrombophlebitis of bilateral femoral vein 451.19  I80.201 Phlebitis/thrombophlebitis of unspecified deep vessels of right lower extremity 451.19  I80.202 Phlebitis/thrombophlebitis of unspecified deep vessels of left lower extremity 451.19  I80.203 Phlebitis/thrombophlebitis of unspecified deep vessels of bilateral lower extremity 451.19  I80.209 Phlebitis/thrombophlebitis of unspecified deep vessels of unspecified lower extremity 451.19  I80.221 Phlebitis/thrombophlebitis of right popliteal vein  451.19  I80.222 Phlebitis/thrombophlebitis of right popliteal vein 451.19  I80.223 Phlebitis/thrombophlebitis of bilateral popliteal vein 451.19  I80.229 Phlebitis/thrombophlebitis of unspecified popliteal vein 451.19  I80.231 Phlebitis/thrombophlebitis of right tibial vein  451.19  I80.232 Phlebitis/thrombophlebitis of right tibial vein 451.19  I80.233 Phlebitis/thrombophlebitis of bilateral tibial vein 451.19  I80.239 Phlebitis/thrombophlebitis of unspecified tibial vein 451.19  I80.291 Phlebitis/thrombophlebitis of other deep vessels of right lower extremity 451.19  I80.292 Phlebitis/thrombophlebitis of other deep vessels of left lower extremity 451.19  I80.293 Phlebitis/thrombophlebitis of other deep vessels of bilateral lower extremity 451.19  I80.299 Phlebitis/thrombophlebitis of other deep vessels of unspecified lower extremity 
Code Sepsis I protocol Version 3.0 
 40 ICD-9 ICD-10 Description (from ICD-10) — CONTINUED  451.81  I80.211  Phlebitis/thrombophlebitis of right iliac vein 451.81   I80.212 Phlebitis/thrombophlebitis of left iliac vein 451.81   I80.213  Phlebitis/thrombophlebitis of bilateral iliac vein 453.81   I80.219  Phlebitis/thrombophlebitis of unspecified iliac vein 451.83   Phlebitis/thrombophlebitis of deep vein of upper extremity 453.40  I82.401 Acute embolism/thrombosis of unspecified deep veins of right lower extremity 453.40  I82.402 Acute embolism/thrombosis of unspecified deep veins of left lower extremity 453.40  I82.403 Acute embolism/thrombosis of unspecified deep veins of bilateral lower extremity 453.40  I82.409 Acute embolism/thrombosis of unspecified deep veins of unspecified lower extremity 453.40  I82.491 Acute embolism/thrombosis of other deep veins of right lower extremity 453.40  I82.492 Acute embolism/thrombosis of other deep veins of left lower extremity 453.40  I82.493 Acute embolism/thrombosis of other deep veins of bilateral lower extremity 453.40  I82.499 Acute embolism/thrombosis of other deep veins of unspecified lower extremity 453.41  I82.411 Acute embolism/thrombosis of right femoral vein 453.41  I82.412 Acute embolism/thrombosis of left femoral vein 453.41  I82.413 Acute embolism/thrombosis of bilateral femoral vein 453.41  I82.419 Acute embolism/thrombosis of unspecified femoral vein 453.41  I82.421 Acute embolism/thrombosis of right iliac vein 453.41  I82.422 Acute embolism/thrombosis of left iliac vein 453.41  I82.423 Acute embolism/thrombosis of bilateral iliac vein 453.41  I82.429 Acute embolism/thrombosis of unspecified iliac vein 453.41  I82.4Y1 Acute embolism/thrombosis of unspecified veins of right proximal lower extremity 453.41  I82.4Y2 Acute embolism/thrombosis of unspecified veins of left proximal lower extremity 453.41  I82.4Y3 Acute embolism/thrombosis of unspecified veins of bilateral proximal lower extremity 453.41  I82.4Y9 Acute embolism/thrombosis of unspecified veins of unspecified prox lower extremity 453.42  I82.431 Acute embolism/thrombosis of right popliteal vein 453.42  I82.432 Acute embolism/thrombosis of left popliteal vein 453.42  I82.433 Acute embolism/thrombosis of bilateral popliteal vein 453.42  I82.439 Acute embolism/thrombosis of unspecified popliteal vein 453.42  I82.441 Acute embolism/thrombosis of right tibial vein 453.42  I82.442 Acute embolism/thrombosis of left tibial vein 453.42  I82.443 Acute embolism/thrombosis of bilateral tibial vein 453.42  I82.449 Acute embolism/thrombosis of unspecified tibial vein 453.42  I82.4Z1 Acute embolism/thrombosis of unspecified veins of right distal lower extremity 453.42  I82.4Z2 Acute embolism/thrombosis of unspecified veins of left distal lower extremity 453.42  I82.4Z3 Acute embolism/thrombosis of unspecified veins of bilateral distal lower extremity 453.42  I82.4Z9 Acute embolism/thrombosis of unspecified veins of unspecified distal lower extremity   I82.621 Acute embolism/thrombosis of deep veins of right upper extremity   I82.622 Acute embolism/thrombosis of deep veins of left upper extremity   I82.623 Acute embolism/thrombosis of deep veins of bilateral upper extremity   I82.629 Acute embolism/thrombosis of deep veins of unspecified upper extremity   
Code Sepsis I protocol Version 3.0 
 41  ICD-9 ICD-10 Description (from ICD-10) — CONTINUED  671.[ADDRESS_436882] trimester  671.40  O87.1 Deep phlebothrombosis, postpartum, unspecified as to epi[INVESTIGATOR_9694] 671.42  O87.1 Deep phlebothrombosis, postpartum, delivered 671.44  O87.1 Deep phlebothrombosis, postpartum, postpartum condition   Adapted from: 1. White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the [LOCATION_002]. Thromb Res 2010;126:61–67.  2. Kniffin WD, Baron JA, Barrett J, Birkmeyer JD, Anderson FA. The epi[INVESTIGATOR_351478]. Arch Intern Med 1994;154:861–866.     
Code Sepsis I protocol Version 3.0 
 42 APPENDIX C — Diagnosis codes for adverse drug reaction  Adapted from:  Hohl CM, Karpov A, Reddekopp L, Doyle-Waters M, Stausberg J. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc. 2014;21:547–57.   ICD-10-CM Anaphylaxis Description A0471  Enterocolitis due to Clostridium difficile, recurrent A0472  Enterocolitis due to Clostridium difficile, not specified as recurrent D590  Drug-induced autoimmune hemolytic anemia D592  Drug-induced nonautoimmune hemolytic anemia D7212  Drug rash with eosinophilia and systemic symptoms syndrome E064  Drug-induced thyroiditis E160  Drug-induced hypoglycemia without coma G210  Malignant neuroleptic syndrome G2402  Drug induced acute dystonia G2409  Other drug induced dystonia G251  Drug-induced tremor G4440  Drug-induced headache, not elsewhere classified, not intractable G4441  Drug-induced headache, not elsewhere classified, intractable G620  Drug-induced polyneuropathy G720  Drug-induced myopathy I427  Cardiomyopathy due to drug and external agent I952  Hypotension due to drugs J702  Acute drug-induced interstitial lung disorders J704  Drug-induced interstitial lung disorders, unspecified K710  Toxic liver disease with cholestasis K7110  Toxic liver disease with hepatic necrosis, without coma K7111  Toxic liver disease with hepatic necrosis, with coma K712  Toxic liver disease with acute hepatitis K716  Toxic liver disease with hepatitis, not elsewhere classified K719  Toxic liver disease, unspecified K8530  Drug induced acute pancreatitis without necrosis or infection K8531  Drug induced acute pancreatitis with uninfected necrosis K8532  Drug induced acute pancreatitis with infected necrosis L233  Allergic contact [CONTACT_351507] L244  Irritant contact [CONTACT_351507] L251  Unspecified contact [CONTACT_351507] L270  Generalized skin eruption due to drugs and medicaments taken internally L271  Localized skin eruption due to drugs and medicaments taken internally L278  Dermatitis due to other substances taken internally L279  Dermatitis due to unspecified substance taken internally L500  Allergic urticaria L509  Urticaria, unspecified L510  Nonbullous erythema multiforme L511  Stevens-Johnson syndrome L512  Toxic epi[INVESTIGATOR_194] [Lyell] 
Code Sepsis I protocol Version 3.0 
 43 ICD-10-CM Anaphylaxis Description L513  Stevens-Johnson syndrome-toxic epi[INVESTIGATOR_351479] L518  Other erythema multiforme L519  Erythema multiforme, unspecified L52  Erythema nodosum L530  Toxic erythema L531  Erythema annulare centrifugum N141  Nephropathy induced by [CONTACT_351508], medicaments and biological substances N142  Nephropathy induced by [CONTACT_351509], medicament or biological substance N144  Toxic nephropathy, not elsewhere classified R502  Drug induced fever T360X1A  Poisoning by [CONTACT_351510], accidental (unintentional), initial encounter T360X1D  Poisoning by [CONTACT_351510], accidental (unintentional), subsequent encounter T360X1S  Poisoning by [CONTACT_351510], accidental (unintentional), sequela T360X4A  Poisoning by [CONTACT_351510], undetermined, initial encounter T360X4D  Poisoning by [CONTACT_351510], undetermined, subsequent encounter T360X4S  Poisoning by [CONTACT_351510], undetermined, sequela T360X5A  Adverse effect of penicillins, initial encounter T360X5D  Adverse effect of penicillins, subsequent encounter T360X5S  Adverse effect of penicillins, sequela T360X6A  Underdosing of penicillins, initial encounter T360X6D  Underdosing of penicillins, subsequent encounter T360X6S  Underdosing of penicillins, sequela T361X1A  Poisoning by [CONTACT_351511]-lactam antibiotics, accidental (unintentional), initial encounter T361X1D  Poisoning by [CONTACT_351511]-lactam antibiotics, accidental (unintentional), subsequent encounter T361X1S  Poisoning by [CONTACT_351511]-lactam antibiotics, accidental (unintentional), sequela T361X4A  Poisoning by [CONTACT_351511]-lactam antibiotics, undetermined, initial encounter T361X4D  Poisoning by [CONTACT_351511]-lactam antibiotics, undetermined, subsequent encounter T361X4S  Poisoning by [CONTACT_351511]-lactam antibiotics, undetermined, sequela T361X5A  Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter T361X5D  Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter T361X5S  Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela T361X6A  Underdosing of cephalosporins and other beta-lactam antibiotics, initial encounter T361X6D  Underdosing of cephalosporins and other beta-lactam antibiotics, subsequent encounter T361X6S  Underdosing of cephalosporins and other beta-lactam antibiotics, sequela 
Code Sepsis I protocol Version 3.0 
 44 ICD-10-CM Anaphylaxis Description T362X1A  Poisoning by [CONTACT_351512], accidental (unintentional), initial encounter T362X1D  Poisoning by [CONTACT_351512], accidental (unintentional), subsequent encounter T362X1S  Poisoning by [CONTACT_351512], accidental (unintentional), sequela T362X4A  Poisoning by [CONTACT_351512], undetermined, initial encounter T362X4D  Poisoning by [CONTACT_351512], undetermined, subsequent encounter T362X4S  Poisoning by [CONTACT_351512], undetermined, sequela T362X5A  Adverse effect of chloramphenicol group, initial encounter T362X5D  Adverse effect of chloramphenicol group, subsequent encounter T362X5S  Adverse effect of chloramphenicol group, sequela T362X6A  Underdosing of chloramphenicol group, initial encounter T362X6D  Underdosing of chloramphenicol group, subsequent encounter T362X6S  Underdosing of chloramphenicol group, sequela T363X1A  Poisoning by [CONTACT_351513], accidental (unintentional), initial encounter T363X1D  Poisoning by [CONTACT_351513], accidental (unintentional), subsequent encounter T363X1S  Poisoning by [CONTACT_351513], accidental (unintentional), sequela T363X4A  Poisoning by [CONTACT_351513], undetermined, initial encounter T363X4D  Poisoning by [CONTACT_351513], undetermined, subsequent encounter T363X4S  Poisoning by [CONTACT_351513], undetermined, sequela T363X5A  Adverse effect of macrolides, initial encounter T363X5D  Adverse effect of macrolides, subsequent encounter T363X5S  Adverse effect of macrolides, sequela T363X6A  Underdosing of macrolides, initial encounter T363X6D  Underdosing of macrolides, subsequent encounter T363X6S  Underdosing of macrolides, sequela T364X1A  Poisoning by [CONTACT_351514], accidental (unintentional), initial encounter T364X1D  Poisoning by [CONTACT_351514], accidental (unintentional), subsequent encounter T364X1S  Poisoning by [CONTACT_351514], accidental (unintentional), sequela T364X4A  Poisoning by [CONTACT_351514], undetermined, initial encounter T364X4D  Poisoning by [CONTACT_351514], undetermined, subsequent encounter T364X4S  Poisoning by [CONTACT_351514], undetermined, sequela T364X5A  Adverse effect of tetracyclines, initial encounter T364X5D  Adverse effect of tetracyclines, subsequent encounter T364X5S  Adverse effect of tetracyclines, sequela T364X6A  Underdosing of tetracyclines, initial encounter T364X6D  Underdosing of tetracyclines, subsequent encounter T364X6S  Underdosing of tetracyclines, sequela T365X1A  Poisoning by [CONTACT_351515], accidental (unintentional), initial encounter T365X1D  Poisoning by [CONTACT_351515], accidental (unintentional), subsequent encounter T365X1S  Poisoning by [CONTACT_351515], accidental (unintentional), sequela T365X4A  Poisoning by [CONTACT_351515], undetermined, initial encounter 
Code Sepsis I protocol Version 3.[ADDRESS_436883] of aminoglycosides, sequela T365X6A  Underdosing of aminoglycosides, initial encounter T365X6D  Underdosing of aminoglycosides, subsequent encounter T365X6S  Underdosing of aminoglycosides, sequela T366X1A  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], accidental (unintentional), initial encounter T366X1D  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], accidental (unintentional), subsequent encounter T366X1S  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], accidental (unintentional), sequela T366X4A  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], undetermined, initial encounter T366X4D  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], undetermined, subsequent encounter T366X4S  Poisoning by [CONTACT_21446][INVESTIGATOR_351480], undetermined, sequela T366X5A  Adverse effect of rifampi[INVESTIGATOR_351480], initial encounter T366X5D  Adverse effect of rifampi[INVESTIGATOR_351480], subsequent encounter T366X5S  Adverse effect of rifampi[INVESTIGATOR_351480], sequela T366X6A  Underdosing of rifampi[INVESTIGATOR_351480], initial encounter T366X6D  Underdosing of rifampi[INVESTIGATOR_351480], subsequent encounter T366X6S  Underdosing of rifampi[INVESTIGATOR_351480], sequela T367X1A  Poisoning by [CONTACT_351516], systemically used, accidental (unintentional), initial encounter T367X1D  Poisoning by [CONTACT_351516], systemically used, accidental (unintentional), subsequent encounter T367X1S  Poisoning by [CONTACT_351516], systemically used, accidental (unintentional), sequela T367X4A  Poisoning by [CONTACT_351516], systemically used, undetermined, initial encounter T367X4D  Poisoning by [CONTACT_351516], systemically used, undetermined, subsequent encounter T367X4S  Poisoning by [CONTACT_351516], systemically used, undetermined, sequela T367X5A  Adverse effect of antifungal antibiotics, systemically used, initial encounter T367X5D  Adverse effect of antifungal antibiotics, systemically used, subsequent encounter T367X5S  Adverse effect of antifungal antibiotics, systemically used, sequela T367X6A  Underdosing of antifungal antibiotics, systemically used, initial encounter T367X6D  Underdosing of antifungal antibiotics, systemically used, subsequent encounter T367X6S  Underdosing of antifungal antibiotics, systemically used, sequela T368X1A  Poisoning by [CONTACT_351517], accidental (unintentional), initial encounter T368X1D  Poisoning by [CONTACT_351517], accidental (unintentional), subsequent encounter T368X1S  Poisoning by [CONTACT_351517], accidental (unintentional), 
Code Sepsis I protocol Version 3.[ADDRESS_436884] of other systemic antibiotics, sequela T368X6A  Underdosing of other systemic antibiotics, initial encounter T368X6D  Underdosing of other systemic antibiotics, subsequent encounter T368X6S  Underdosing of other systemic antibiotics, sequela T3691XA  Poisoning by [CONTACT_351518], accidental (unintentional), initial encounter T3691XD  Poisoning by [CONTACT_351518], accidental (unintentional), subsequent encounter T3691XS  Poisoning by [CONTACT_351518], accidental (unintentional), sequela T3694XA  Poisoning by [CONTACT_351518], undetermined, initial encounter T3694XD  Poisoning by [CONTACT_351518], undetermined, subsequent encounter T3694XS  Poisoning by [CONTACT_351518], undetermined, sequela T3695XA  Adverse effect of unspecified systemic antibiotic, initial encounter T3695XD  Adverse effect of unspecified systemic antibiotic, subsequent encounter T3695XS  Adverse effect of unspecified systemic antibiotic, sequela T3696XA  Underdosing of unspecified systemic antibiotic, initial encounter T3696XD  Underdosing of unspecified systemic antibiotic, subsequent encounter T3696XS  Underdosing of unspecified systemic antibiotic, sequela T370X1A  Poisoning by [CONTACT_115137], accidental (unintentional), initial encounter T370X1D  Poisoning by [CONTACT_115137], accidental (unintentional), subsequent encounter T370X1S  Poisoning by [CONTACT_115137], accidental (unintentional), sequela T370X4A  Poisoning by [CONTACT_115137], undetermined, initial encounter T370X4D  Poisoning by [CONTACT_115137], undetermined, subsequent encounter T370X4S  Poisoning by [CONTACT_115137], undetermined, sequela T370X5A  Adverse effect of sulfonamides, initial encounter T370X5D  Adverse effect of sulfonamides, subsequent encounter T370X5S  Adverse effect of sulfonamides, sequela T370X6A  Underdosing of sulfonamides, initial encounter T370X6D  Underdosing of sulfonamides, subsequent encounter T370X6S  Underdosing of sulfonamides, sequela T371X1A  Poisoning by [CONTACT_351519], accidental (unintentional), initial encounter T371X1D  Poisoning by [CONTACT_351519], accidental (unintentional), subsequent encounter T371X1S  Poisoning by [CONTACT_351519], accidental (unintentional), sequela T371X4A  Poisoning by [CONTACT_351519], undetermined, initial encounter 
Code Sepsis I protocol Version 3.[ADDRESS_436885] of antimycobacterial drugs, sequela T371X6A  Underdosing of antimycobacterial drugs, initial encounter T371X6D  Underdosing of antimycobacterial drugs, subsequent encounter T371X6S  Underdosing of antimycobacterial drugs, sequela T372X1A  Poisoning by [CONTACT_351520], accidental (unintentional), initial encounter T372X1D  Poisoning by [CONTACT_351520], accidental (unintentional), subsequent encounter T372X1S  Poisoning by [CONTACT_351520], accidental (unintentional), sequela T372X4A  Poisoning by [CONTACT_351520], undetermined, initial encounter T372X4D  Poisoning by [CONTACT_351520], undetermined, subsequent encounter T372X4S  Poisoning by [CONTACT_351520], undetermined, sequela T372X5A  Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter T372X5D  Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter T372X5S  Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela T372X6A  Underdosing of antimalarials and drugs acting on other blood protozoa, initial encounter T372X6D  Underdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter T372X6S  Underdosing of antimalarials and drugs acting on other blood protozoa, sequela T373X1A  Poisoning by [CONTACT_351521], accidental (unintentional), initial encounter T373X1D  Poisoning by [CONTACT_351521], accidental (unintentional), subsequent encounter T373X1S  Poisoning by [CONTACT_351521], accidental (unintentional), sequela T373X4A  Poisoning by [CONTACT_351521], undetermined, initial encounter T373X4D  Poisoning by [CONTACT_351521], undetermined, subsequent encounter T373X4S  Poisoning by [CONTACT_351521], undetermined, sequela T373X5A  Adverse effect of other antiprotozoal drugs, initial encounter T373X5D  Adverse effect of other antiprotozoal drugs, subsequent encounter T373X5S  Adverse effect of other antiprotozoal drugs, sequela T373X6A  Underdosing of other antiprotozoal drugs, initial encounter 
Code Sepsis I protocol Version 3.0 
 48 ICD-10-CM Anaphylaxis Description T373X6D  Underdosing of other antiprotozoal drugs, subsequent encounter T373X6S  Underdosing of other antiprotozoal drugs, sequela T374X1A  Poisoning by [CONTACT_351522], accidental (unintentional), initial encounter T374X1D  Poisoning by [CONTACT_351522], accidental (unintentional), subsequent encounter T374X1S  Poisoning by [CONTACT_351522], accidental (unintentional), sequela T374X4A  Poisoning by [CONTACT_351522], undetermined, initial encounter T374X4D  Poisoning by [CONTACT_351522], undetermined, subsequent encounter T374X4S  Poisoning by [CONTACT_351522], undetermined, sequela T374X5A  Adverse effect of anthelminthics, initial encounter T374X5D  Adverse effect of anthelminthics, subsequent encounter T374X5S  Adverse effect of anthelminthics, sequela T374X6A  Underdosing of anthelminthics, initial encounter T374X6D  Underdosing of anthelminthics, subsequent encounter T374X6S  Underdosing of anthelminthics, sequela T375X1A  Poisoning by [CONTACT_351523], accidental (unintentional), initial encounter T375X1D  Poisoning by [CONTACT_351523], accidental (unintentional), subsequent encounter T375X1S  Poisoning by [CONTACT_351523], accidental (unintentional), sequela T375X4A  Poisoning by [CONTACT_351523], undetermined, initial encounter T375X4D  Poisoning by [CONTACT_351523], undetermined, subsequent encounter T375X4S  Poisoning by [CONTACT_351523], undetermined, sequela T375X5A  Adverse effect of antiviral drugs, initial encounter T375X5D  Adverse effect of antiviral drugs, subsequent encounter T375X5S  Adverse effect of antiviral drugs, sequela T375X6A  Underdosing of antiviral drugs, initial encounter T375X6D  Underdosing of antiviral drugs, subsequent encounter T375X6S  Underdosing of antiviral drugs, sequela T378X1A  Poisoning by [CONTACT_351524]-infectives and antiparasitics, accidental (unintentional), initial encounter T378X1D  Poisoning by [CONTACT_351524]-infectives and antiparasitics, accidental (unintentional), subsequent encounter T378X1S  Poisoning by [CONTACT_351524]-infectives and antiparasitics, accidental (unintentional), sequela T378X4A  Poisoning by [CONTACT_351524]-infectives and antiparasitics, undetermined, initial encounter T378X4D  Poisoning by [CONTACT_351524]-infectives and antiparasitics, undetermined, subsequent encounter T378X4S  Poisoning by [CONTACT_351524]-infectives and antiparasitics, undetermined, sequela T378X5A  Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter T378X5D  Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter T378X5S  Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela T378X6A  Underdosing of other specified systemic anti-infectives and antiparasitics, 
Code Sepsis I protocol Version 3.0 
 49 ICD-10-CM Anaphylaxis Description initial encounter T378X6D  Underdosing of other specified systemic anti-infectives and antiparasitics, subsequent encounter T378X6S  Underdosing of other specified systemic anti-infectives and antiparasitics, sequela T3791XA  Poisoning by [CONTACT_351525]-infective and antiparasitics, accidental (unintentional), initial encounter T3791XD  Poisoning by [CONTACT_351525]-infective and antiparasitics, accidental (unintentional), subsequent encounter T3791XS  Poisoning by [CONTACT_351525]-infective and antiparasitics, accidental (unintentional), sequela T3794XA  Poisoning by [CONTACT_351525]-infective and antiparasitics, undetermined, initial encounter T3794XD  Poisoning by [CONTACT_351525]-infective and antiparasitics, undetermined, subsequent encounter T3794XS  Poisoning by [CONTACT_351525]-infective and antiparasitics, undetermined, sequela T3795XA  Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter T3795XD  Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter T3795XS  Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela T3796XA  Underdosing of unspecified systemic anti-infectives and antiparasitics, initial encounter T3796XD  Underdosing of unspecified systemic anti-infectives and antiparasitics, subsequent encounter T3796XS  Underdosing of unspecified systemic anti-infectives and antiparasitics, sequela T431X5A  Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter T431X5D  Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter T431X5S  Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela T43215A  Adverse effect of selective serotonin and norepi[INVESTIGATOR_5608], initial encounter T43215D  Adverse effect of selective serotonin and norepi[INVESTIGATOR_5608], subsequent encounter T43215S  Adverse effect of selective serotonin and norepi[INVESTIGATOR_5608], sequela T43225A  Adverse effect of selective serotonin reuptake inhibitors, initial encounter T43225D  Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter T43225S  Adverse effect of selective serotonin reuptake inhibitors, sequela T50901A  Poisoning by [CONTACT_351526], medicaments and biological substances, accidental (unintentional), initial encounter T50901D  Poisoning by [CONTACT_351526], medicaments and biological substances, 
Code Sepsis I protocol Version 3.0 
 50 ICD-10-CM Anaphylaxis Description accidental (unintentional), subsequent encounter T50901S  Poisoning by [CONTACT_351526], medicaments and biological substances, accidental (unintentional), sequela T50904A  Poisoning by [CONTACT_351526], medicaments and biological substances, undetermined, initial encounter T50904D  Poisoning by [CONTACT_351526], medicaments and biological substances, undetermined, subsequent encounter T50904S  Poisoning by [CONTACT_351526], medicaments and biological substances, undetermined, sequela T50905A  Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter T50905D  Adverse effect of unspecified drugs, medicaments and biological substances, subsequent encounter T50905S  Adverse effect of unspecified drugs, medicaments and biological substances, sequela T50906A  Underdosing of unspecified drugs, medicaments and biological substances, initial encounter T50906D  Underdosing of unspecified drugs, medicaments and biological substances, subsequent encounter T50906S  Underdosing of unspecified drugs, medicaments and biological substances, sequela T50991A  Poisoning by [CONTACT_351508], medicaments and biological substances, accidental (unintentional), initial encounter T50991D  Poisoning by [CONTACT_351508], medicaments and biological substances, accidental (unintentional), subsequent encounter T50991S  Poisoning by [CONTACT_351508], medicaments and biological substances, accidental (unintentional), sequela T50994A  Poisoning by [CONTACT_351508], medicaments and biological substances, undetermined, initial encounter T50994D  Poisoning by [CONTACT_351508], medicaments and biological substances, undetermined, subsequent encounter T50994S  Poisoning by [CONTACT_351508], medicaments and biological substances, undetermined, sequela T50995A  Adverse effect of other drugs, medicaments and biological substances, initial encounter T50995D  Adverse effect of other drugs, medicaments and biological substances, subsequent encounter T50995S  Adverse effect of other drugs, medicaments and biological substances, sequela T50996A  Underdosing of other drugs, medicaments and biological substances, initial encounter T50996D  Underdosing of other drugs, medicaments and biological substances, subsequent encounter T50996S  Underdosing of other drugs, medicaments and biological substances, sequela T782XXA X Anaphylactic shock, unspecified, initial encounter T782XXD X Anaphylactic shock, unspecified, subsequent encounter 
Code Sepsis I protocol Version 3.[ADDRESS_436886] dilution of fluid used during infusion Y638  Failure in dosage during other surgical and medical care Y639  Failure in dosage during unspecified surgical and medical care Y640  Contaminated medical or biological substance, transfused or infused Y641  Contaminated medical or biological substance, injected or used for immunization Y651  Wrong fluid used in infusion Y66  Nonadministration of surgical and medical care Y69  Unspecified misadventure during surgical and medical care  